Could a common diabetes drug help fight brain tumors?
NCT ID NCT07541781
First seen May 01, 2026 · Last updated Jun 19, 2026 · Updated 13 times
Summary
This early-phase trial is testing whether sitagliptin, a drug used for diabetes, can help treat recurrent grade 4 glioma (a severe brain cancer) when combined with the standard drug bevacizumab. The study involves 45 adults whose cancer has returned after initial treatment. Researchers aim to find the safest dose of sitagliptin and see if it changes certain immune cells in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Iowa Health Care
RECRUITINGIowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sitagliptin (a diabetes drug) combined with bevacizumab (Avastin, a cancer drug)
What this could lead to
If it works, this could point toward a new treatment option for recurrent glioblastoma, a tough-to-treat brain cancer.
What could go wrong
This is a very early Phase 1 trial with only 45 people. The main goal is safety and dosing, not yet proof of effectiveness. Side effects from the drug combination are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.